12.49
前日終値:
$13.32
開ける:
$13.36
24時間の取引高:
416.79K
Relative Volume:
1.01
時価総額:
$321.94M
収益:
-
当期純損益:
$-52.60M
株価収益率:
-9.3481
EPS:
-1.3361
ネットキャッシュフロー:
$-35.80M
1週間 パフォーマンス:
-14.45%
1か月 パフォーマンス:
-16.82%
6か月 パフォーマンス:
+76.16%
1年 パフォーマンス:
+122.24%
Tenax Therapeutics Inc Stock (TENX) Company Profile
名前
Tenax Therapeutics Inc
セクター
電話
919-855-2100
住所
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TENX
Tenax Therapeutics Inc
|
12.49 | 321.94M | 0 | -52.60M | -35.80M | -1.3361 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 開始されました | Piper Sandler | Overweight |
| 2024-10-24 | 開始されました | Leerink Partners | Outperform |
| 2024-10-14 | 開始されました | Guggenheim | Buy |
| 2024-09-30 | 開始されました | William Blair | Outperform |
| 2017-05-18 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 開始されました | MLV & Co | Buy |
| 2014-11-18 | 開始されました | WallachBeth | Buy |
すべてを表示
Tenax Therapeutics Inc (TENX) 最新ニュース
Tenax Therapeutics names Timothy Healey as chief commercial officer By Investing.com - Investing.com Australia
Invus affiliates disclose 2.1% stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax brings in drug launch veteran Timothy Healey to prep TNX-103 - Stock Titan
Tenax Therapeutics, Inc. Appoints Timothy Healey as Chief Commercial Officer, Effective May 4, 2026 - marketscreener.com
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics appoints Thomas Staab as chief financial officer - MSN
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans - Sahm
Discipline and Rules-Based Execution in TENX Response - Stock Traders Daily
How do interest rates affect Tenax Therapeutics (TENX) stock | Q4 2025: Profit Exceeds ViewsSpin Off - Newser
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving AverageHere's What Happened - MarketBeat
Tenax Therapeutics names new CFO - MSN
Tenax Therapeutics names Thomas Staab as chief financial officer By Investing.com - Investing.com India
Tenax Therapeutics (TENX) Stock Movers | Q4 2025: EPS Tops ViewsStock Analysis Community - UBND thành phố Hải Phòng
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth - Yahoo Finance
Tenax Therapeutics Names New CFO to Support Growth - TipRanks
Tenax Therapeutics names Thomas Staab as chief financial officer - Investing.com
[ARS] TENAX THERAPEUTICS, INC. SEC Filing - Stock Titan
Tenax Therapeutics (NASDAQ: TENX) 2026 proxy details director slate, auditor vote - Stock Titan
Tenax Therapeutics (NASDAQ: TENX) hires new CFO Thomas Staab with equity grants - Stock Titan
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer - The Manila Times
Tenax Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
TENX SEC FilingsTenax Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Tenax Therapeutics (TENX) Stock Index Trade (Ticks Lower) 2026-04-20Retail Flow - Cổng thông tin điện tử Tỉnh Sơn La
Behavioral Patterns of TENX and Institutional Flows - Stock Traders Daily
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Panic Selling: Is Tenax Therapeutics Inc forming a double bottom2026 Institutional & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Is Tenax Therapeutics (TENX) Stock Priced Correctly | Price at $14.27, Down 1.11%Watchlist - Newser
CEO Moves: Is Tenax Therapeutics Inc forming a double bottom2026 Market Overview & Short-Term Trading Alerts - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX) and Ligand Pharma (LGND) - The Globe and Mail
If You Invested $1,000 in Tenax Therapeutics Inc (TENX) - Stock Titan
TENX Options Volatility — NASDAQ:TENX - TradingView
TENX Options Chain — NASDAQ:TENX - TradingView
TENAX Therapeutics (NASDAQ: TENX) — Morgan Stanley reports 3.5%/3.4% positions - Stock Titan
[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure - Stock Titan
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Is Tenax Therapeutics (TENX) Stock Suitable for 2026 | Price at $14.59, Down 1.95%Upside Potential - UBND thành phố Hải Phòng
(TENX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
TENX Should I Buy - Intellectia AI
[EFFECT] TENAX THERAPEUTICS, INC. SEC Filing - Stock Titan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Volume Summary: What are Tenax Therapeutics Incs recent SEC filings showingOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView — Track All Markets
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax Therapeutics Inc (TENX) 財務データ
収益
当期純利益
現金流量
EPS
Tenax Therapeutics Inc (TENX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
大文字化:
|
ボリューム (24 時間):